Related references
Note: Only part of the references are listed.Elimination Pathways of Nanoparticles
Wilson Poon et al.
ACS NANO (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium
Shima Gholizadeh et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma
Kin Man Au et al.
ACS NANO (2018)
Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
Li Tian et al.
DRUG DELIVERY (2018)
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Kelly Valla et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
Kerrie Faia et al.
PLOS ONE (2018)
A Revisit to the Pretargeting Concept-A Target Conversion
Guozheng Liu
FRONTIERS IN PHARMACOLOGY (2018)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
New insights into the pretargeting approach to image and treat tumours
Malay Patra et al.
CHEMICAL SOCIETY REVIEWS (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S. Blachly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
Jason R. Westin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
B-cell receptor signaling as a driver of lymphoma development and evolution
Carsten U. Niemann et al.
SEMINARS IN CANCER BIOLOGY (2013)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
Francesco Dituri et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner et al.
CLINICAL CANCER RESEARCH (2011)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Jatin Roper et al.
PLOS ONE (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection
Jered B. Haun et al.
NATURE NANOTECHNOLOGY (2010)
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
John M. Pagel et al.
BLOOD (2009)
Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas
Elias Drakos et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Improved tumor targeting by combined use of two antitenascin antibodies
F Petronzelli et al.
CLINICAL CANCER RESEARCH (2005)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
The mechanisms of action of rituximab in the elimination of tumor cells
P Johnson et al.
SEMINARS IN ONCOLOGY (2003)